Improvement of hemodynamics with the ADVOS Therapy
Not yet recruiting
- Conditions
- Critical ill patients in the IC
- Registration Number
- DRKS00031279
- Lead Sponsor
- niklinik RWTH Aachen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Indication for multiorgan support with ADVOS therapy
Exclusion Criteria
Age < 18 years
Pregnancy
Contraindication for ADVOS therapy
Moribund patient (life expectancy < 24 hours)
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite outcome of acid-base balance correction and reduction of catecholamine dose after three consecutive 24-hour ADVOS sessions
- Secondary Outcome Measures
Name Time Method Reduction in serum lactate levels<br>Reduction in cytokine levels (IL-6, IL-10)<br>Changes in regional oxygen saturation (rSO2) (through in-vivo optical spectroscopy: i.e., INVOS system) <br>Hemodynamic changes during connection to and disconnection from the ADVOS multi (through Transpulmonary Thermodilution: i.e., PiCCO)<br>Feasibility of ultrafiltration (% of patients reaching 80% of the target fluid removal)<br>Improvement of pulmonary edema and capillary leak (i.e., reduction of EVLWI and PVPI)<br>Removal of water-soluble and protein-bound substances (e.g., bilirubin, creatinine, BUN)<br>ICU-LOS<br>28-day, ICU- and Hospital-Mortality<br>